← Back to Search

Thrombectomy Device

JETi™ Hydrodynamic Thrombectomy System for Peripheral Artery Disease (JETi Trial)

N/A
Recruiting
Research Sponsored by Walk Vascular LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days post-index procedure
Awards & highlights

Summary

The JETi Registry is a prospective, single-arm, multi-center study to collect real-world data on the safety, performance, and clinical benefits of the JETi™ Hydrodynamic Thrombectomy System (JETi System) for the treatment of acute/subacute thrombosis in the peripheral vasculature. This post-market study will register approximately 280 subjects at approximately 30 centers Globally. Subjects participating in this Registry will be followed through their 12-month follow up visit.

Eligible Conditions
  • Deep Vein Thrombosis
  • Peripheral Artery Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days post-index procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days post-index procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
For Arterial Subjects: Clot removal grade for each JETi-treated vessel
For Arterial Subjects: Composite of JETi-related major adverse events (MAEs)
For Venous Subjects: Composite of JETi-related major adverse events (MAEs)
Secondary study objectives
Technical Success

Trial Design

1Treatment groups
Experimental Treatment
Group I: JETi™ Hydrodynamic Thrombectomy SystemExperimental Treatment1 Intervention
Subjects who were treated with JETi™ Hydrodynamic Thrombectomy System will be included.

Find a Location

Who is running the clinical trial?

Walk Vascular LLCLead Sponsor
Abbott Medical DevicesLead Sponsor
647 Previous Clinical Trials
408,254 Total Patients Enrolled
~51 spots leftby Sep 2025